184 related articles for article (PubMed ID: 21237236)
61. Subtype classification of hepatocellular adenoma.
Bioulac-Sage P; Balabaud C; Zucman-Rossi J
Dig Surg; 2010; 27(1):39-45. PubMed ID: 20357450
[TBL] [Abstract][Full Text] [Related]
62. Predictive Patterns of Glutamine Synthetase Immunohistochemical Staining in CTNNB1-mutated Hepatocellular Adenomas.
Sempoux C; Gouw ASH; Dunet V; Paradis V; Balabaud C; Bioulac-Sage P
Am J Surg Pathol; 2021 Apr; 45(4):477-487. PubMed ID: 33560657
[TBL] [Abstract][Full Text] [Related]
63. Wnt/β-catenin signaling as a useful therapeutic target in hepatoblastoma.
Sha YL; Liu S; Yan WW; Dong B
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31511432
[TBL] [Abstract][Full Text] [Related]
64. Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors.
López-Terrada D; Gunaratne PH; Adesina AM; Pulliam J; Hoang DM; Nguyen Y; Mistretta TA; Margolin J; Finegold MJ
Hum Pathol; 2009 Jun; 40(6):783-94. PubMed ID: 19200579
[TBL] [Abstract][Full Text] [Related]
65. Correlation of exon 3 β-catenin mutations with glutamine synthetase staining patterns in hepatocellular adenoma and hepatocellular carcinoma.
Hale G; Liu X; Hu J; Xu Z; Che L; Solomon D; Tsokos C; Shafizadeh N; Chen X; Gill R; Kakar S
Mod Pathol; 2016 Nov; 29(11):1370-1380. PubMed ID: 27469330
[TBL] [Abstract][Full Text] [Related]
66. Novel Advances in Understanding of Molecular Pathogenesis of Hepatoblastoma: A Wnt/β-Catenin Perspective.
Bell D; Ranganathan S; Tao J; Monga SP
Gene Expr; 2017 Feb; 17(2):141-154. PubMed ID: 27938502
[TBL] [Abstract][Full Text] [Related]
67. HGF/c-Met related activation of β-catenin in hepatoblastoma.
Purcell R; Childs M; Maibach R; Miles C; Turner C; Zimmermann A; Sullivan M
J Exp Clin Cancer Res; 2011 Oct; 30(1):96. PubMed ID: 21992464
[TBL] [Abstract][Full Text] [Related]
68. β-Catenin mutations as determinants of hepatoblastoma phenotypes in mice.
Zhang W; Meyfeldt J; Wang H; Kulkarni S; Lu J; Mandel JA; Marburger B; Liu Y; Gorka JE; Ranganathan S; Prochownik EV
J Biol Chem; 2019 Nov; 294(46):17524-17542. PubMed ID: 31597698
[TBL] [Abstract][Full Text] [Related]
69. Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas.
Yamada S; Ohira M; Horie H; Ando K; Takayasu H; Suzuki Y; Sugano S; Hirata T; Goto T; Matsunaga T; Hiyama E; Hayashi Y; Ando H; Suita S; Kaneko M; Sasaki F; Hashizume K; Ohnuma N; Nakagawara A
Oncogene; 2004 Aug; 23(35):5901-11. PubMed ID: 15221005
[TBL] [Abstract][Full Text] [Related]
70. Glutamine synthetase limits β-catenin-mutated liver cancer growth by maintaining nitrogen homeostasis and suppressing mTORC1.
Dai W; Shen J; Yan J; Bott AJ; Maimouni S; Daguplo HQ; Wang Y; Khayati K; Guo JY; Zhang L; Wang Y; Valvezan A; Ding WX; Chen X; Su X; Gao S; Zong WX
J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36256480
[TBL] [Abstract][Full Text] [Related]
71. Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and ubiquitin ligase complex.
Jia D; Dong R; Jing Y; Xu D; Wang Q; Chen L; Li Q; Huang Y; Zhang Y; Zhang Z; Liu L; Zheng S; Xia Q; Wang H; Dong K; He X
Hepatology; 2014 Nov; 60(5):1686-96. PubMed ID: 24912477
[TBL] [Abstract][Full Text] [Related]
72. Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts.
Chiu M; Tardito S; Pillozzi S; Arcangeli A; Armento A; Uggeri J; Missale G; Bianchi MG; Barilli A; Dall'Asta V; Campanini N; Silini EM; Fuchs J; Armeanu-Ebinger S; Bussolati O
Br J Cancer; 2014 Sep; 111(6):1159-67. PubMed ID: 25072259
[TBL] [Abstract][Full Text] [Related]
73. Expression of SLCO1B3 is associated with intratumoral cholestasis and CTNNB1 mutations in hepatocellular carcinoma.
Sekine S; Ogawa R; Ojima H; Kanai Y
Cancer Sci; 2011 Sep; 102(9):1742-7. PubMed ID: 21615622
[TBL] [Abstract][Full Text] [Related]
74. New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism.
Cadoret A; Ovejero C; Terris B; Souil E; Lévy L; Lamers WH; Kitajewski J; Kahn A; Perret C
Oncogene; 2002 Nov; 21(54):8293-301. PubMed ID: 12447692
[TBL] [Abstract][Full Text] [Related]
75. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene.
Cieply B; Zeng G; Proverbs-Singh T; Geller DA; Monga SP
Hepatology; 2009 Mar; 49(3):821-31. PubMed ID: 19101982
[TBL] [Abstract][Full Text] [Related]
76. Multifocal hepatic neoplasia in 3 children with APC gene mutation.
Gupta A; Sheridan RM; Towbin A; Geller JI; Tiao G; Bove KE
Am J Surg Pathol; 2013 Jul; 37(7):1058-66. PubMed ID: 23715166
[TBL] [Abstract][Full Text] [Related]
77. Hepatocellular adenoma classification: a comparative evaluation of immunohistochemistry and targeted mutational analysis.
Margolskee E; Bao F; de Gonzalez AK; Moreira RK; Lagana S; Sireci AN; Sepulveda AR; Remotti H; Lefkowitch JH; Salomao M
Diagn Pathol; 2016 Mar; 11():27. PubMed ID: 26961851
[TBL] [Abstract][Full Text] [Related]
78. Exploration of CTNNB1 ctDNA as a putative biomarker for hepatoblastoma.
Kahana-Edwin S; McCowage G; Cain L; Saletta F; Yuksel A; Graf N; Karpelowsky J
Pediatr Blood Cancer; 2020 Nov; 67(11):e28594. PubMed ID: 32881242
[TBL] [Abstract][Full Text] [Related]
79. β-Catenin and Yes-Associated Protein 1 Cooperate in Hepatoblastoma Pathogenesis.
Min Q; Molina L; Li J; Adebayo Michael AO; Russell JO; Preziosi ME; Singh S; Poddar M; Matz-Soja M; Ranganathan S; Bell AW; Gebhardt R; Gaunitz F; Yu J; Tao J; Monga SP
Am J Pathol; 2019 May; 189(5):1091-1104. PubMed ID: 30794807
[TBL] [Abstract][Full Text] [Related]
80. Upregulated YAP promotes oncogenic CTNNB1 expression contributing to molecular pathology of hepatoblastoma.
Lu S; Jiang M; Chen Q; Luo X; Cao Z; Huang H; Zheng M; Du J
Pediatr Blood Cancer; 2022 Sep; 69(9):e29705. PubMed ID: 35404538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
